Dyne Therapeutics, Inc. (DYN) intrinsic value & 10-year financials
Dyne Therapeutics, Inc. (DYN) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $14.25
- Market cap
- $1.8B
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -248.0%
- Free cash flow (FY2025)
- -$405.1M
DYN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$446.2M | -$3.47 | -$405.1M | — | -205.1% |
| FY2024 | — | -$317.4M | -$3.37 | -$294.7M | — | -334.1% |
| FY2023 | — | -$235.9M | -$3.95 | -$188.9M | — | -491.9% |
| FY2022 | — | -$168.1M | -$3.23 | -$156.7M | — | -111.2% |
| FY2021 | — | -$149.3M | -$2.93 | -$123.2M | — | -125.6% |
| FY2020 | — | -$59.4M | — | -$47.7M | — | -143.2% |
| FY2019 | — | -$14.9M | — | -$13.5M | — | -324.5% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Dyne Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Dyne Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -65.1% ROIC.
Dyne Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Dyne Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.